New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
11:01 EDTTHRX, ZOLT, SA, TROX, TERHigh option volume stocks: THRX ZOLT SA TROX TER
News For THRX;ZOLT;SA;TROX;TER From The Last 14 Days
Check below for free stories on THRX;ZOLT;SA;TROX;TER the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
08:03 EDTTROXTronox announces labor agreement with South African unions
Subscribe for More Information
05:38 EDTTHRXGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
July 9, 2014
06:47 EDTTHRXGlaxoSmithKline, Theravance announces Australia approval of Anoro Ellipta
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use